Home  /  Resource Library  /  OUTCOMES OF RELAPSED/REFRACTORY MCL PATIENTS TREATED WITH ZANUBRUTINIB MONOTHERAPY IN THE SECOND LINE AND IN LATER LINES: A POOLED ANALYSIS FROM 2 STUDIES

OUTCOMES OF RELAPSED/REFRACTORY MCL PATIENTS TREATED WITH ZANUBRUTINIB MONOTHERAPY IN THE SECOND LINE AND IN LATER LINES: A POOLED ANALYSIS FROM 2 STUDIES

EHA 2020: Pooled analysis of studies examining zanubrutinib for treatment of relapsed mantle cell lymphoma.